Skip to main content
Zyvex Zyvex Pharmaceuticals
Photo 1 of 1 Click to zoom

Product photograph of the current pack. Each physical unit carries the same blue-teal ZX label artwork, a batch code and a scratch-off verification panel.

Peptides

TB 500

Thymosin Beta 4

Compound
Thymosin Beta 4
Category
Peptides
Brand
TB 500
Manufacturer
Zyvex Pharmaceuticals
Presentation
vial
Strength
5 mg
Route
Injection
Storage
15–25 °C, protected from light, do not freeze

Batch analysis

Independent batch results for TB 500 are not yet published. They will be added here once testing is complete.

Product information

About TB 500

5 mg · one vial · Zyvex Pharmaceuticals

TB 500 from Zyvex Pharmaceuticals contains 5 mg of thymosin beta-4 in one vial. The vial amount describes total content, not an administered dose.

This prospect summarises composition, clinical considerations and handling. It supports professional review and does not replace an individual prescription or verified instructions for the exact preparation.

Basic Identification & Composition

Product Name & Active Ingredient

TB 500 is associated with thymosin beta-4 in the catalogue. The name TB-500 is also used for a shorter thymosin fragment, so full-length thymosin beta-4 and fragment research must be kept distinct when assessing the preparation.

Qualitative & Quantitative Composition

Property Details
Product name TB 500
Manufacturer Zyvex Pharmaceuticals
Active ingredient Thymosin Beta 4
Strength 5 mg
Package one vial
Drug class Thymosin-related peptide preparation
Molecular composition Sequence-dependent peptide; full-length thymosin beta-4 and TB-500 fragments are distinct
Presentation Vial; preparation and route require formulation-specific instructions

Dosage Form

A vial presentation. A vial may contain a ready-to-use preparation or material requiring preparation, so the exact dosage form must be confirmed before administration. Total milligrams do not establish concentration, injection volume or sterility.

Clinical Particulars

TB 500 uses

TB 500 from Zyvex Pharmaceuticals contains thymosin beta 4. Thymosin beta-4 has been studied for tissue repair, including ophthalmic treatment for dry eye. These studies concern defined formulations and do not demonstrate that a vial sold as TB 500 has the same identity, route or clinical effects.

People seek TB 500 for soft-tissue recovery and return to training. Those goals are not proof of improved healing or of benefit for general wellbeing.

A phase II dry-eye trial investigated a 0.1% topical thymosin beta-4 solution. This is a formulation-specific research example, not an injection protocol. Full-length peptide and peptide fragments are not interchangeable, and a 5 mg vial does not establish a human recovery regimen.

Dosage and Administration

A reliable routine human dosing regimen cannot be established from the available clinical evidence. The product strength must not be converted into a self-treatment schedule. Human use requires an appropriately supervised clinical or research setting with a defined protocol. The 5 mg vial amount does not establish a route, reconstitution volume or treatment schedule. A protocol for full-length thymosin beta-4 cannot be transferred automatically to a fragment.

Contraindications

A complete clinical contraindication profile has not been established. Avoid exposure with known hypersensitivity, during pregnancy or breastfeeding, and in children outside a properly reviewed clinical setting. Absence of a listed contraindication is not evidence of safety.

Warnings and Precautions

Peptide identity, impurities, aggregation and immune reactions are material concerns. Evidence for one thymosin sequence or route does not establish the safety of another. Injection-related infection and allergic reactions remain possible.

Risks and Interactions

Drug & Food Interactions

Human interaction studies are limited. A clinician or study team should review all prescription medicines, nonprescription products and supplements. There is no basis for assuming that combinations with other experimental compounds are safe.

Pregnancy and Lactation

Adequate pregnancy, lactation and reproductive safety evidence is lacking. Avoid exposure during pregnancy or breastfeeding. Any reproductive-risk precautions in a clinical study should be directed by the study team.

Side Effects and Adverse Reactions

A dependable frequency-based adverse-reaction profile cannot be established from the available human evidence. Limited reports cannot rule out uncommon or delayed harm. Seek urgent care for breathing difficulty, facial swelling, collapse or severe symptoms after exposure.

Overdose Protocol

For a suspected overdose, contact a poison-information service or urgent medical care and provide the product, amount, time and other substances taken. Collapse, seizures or breathing difficulty require emergency help. Do not induce vomiting or attempt an antidote at home. Clinical treatment depends on symptoms and the substances involved.

Scientific & Technical Data

Pharmacodynamics

Full-length thymosin beta-4 is an actin-binding peptide involved in cellular organisation and migration. A shorter fragment has different structural properties; describing a product as TB-500 does not make all effects of full-length thymosin beta-4 transferable to it.

Pharmacokinetics

Human pharmacokinetic conclusions depend on the exact peptide sequence and formulation. A clinically reliable half-life, bioavailability or clearance value should not be assigned to an ambiguously named peptide preparation.

Storage and Handling

Keep the sealed container protected from direct light, excessive heat and accidental access. Temperature, transport conditions and expiry must be supported by stability information for the finished preparation. For a vial, any conditions after opening or preparation must also be validated for that formulation. Refrigeration alone does not establish sterility or a safe period of use. Arrange disposal through a pharmacist or the supervising research service.

Product request

Enquire about TB 500

Send a pricing, sample or distribution request. The product (TB 500 (5 mg · vial)) is included automatically, and our team replies within one business day.